Latest Headlines

  1. Trilantic Capital Partners Europe Completes Acquisition Of 90% Stake In Leading Italian Pharmaceuticals Producer Doppel Farmaceutici

    Trilantic Capital Partners Europe (“Trilantic Europe”), a private equity firm focused on mid-market transactions in Europe, announces recently that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici (“Doppel” or the “Company”), after obtaining anti-trust approvals.

  2. Regeneron And Sanofi Announce Publication Of Positive Phase 2b Dupilumab Data In The Lancet

    Regeneron Pharmaceuticals, Inc. and Sanofi recently announced the publication in The Lancet of results from a Phase 2b 16-week, dose-ranging study of dupilumab, an investigational therapy, in 380 adult patients with moderate-to-severe atopic dermatitis who were not adequately controlled on topical corticosteroids. Dupilumab is an investigational therapy that inhibits signaling of IL-4 and IL-13, two key cytokines required for the T helper 2 (Th2) immune response.

  3. Could Laws And Regulations Price Consumers Out Of Generic Drugs?

    A new study by National Center for Policy Analysis finds that drugs are the best bargain in the health care system – but that may change if recent price hikes continue.

  4. Fast, Accurate Total Organic Carbon (TOC) Analysis From Beckman Coulter Life Sciences

    New Instrument Helps Pharma Labs Comply with Global Quality Requirements

  5. Orphan-Drug Designation From FDA And Positive Scientific Advice From EMA

    Ability Pharmaceuticals, a drug development biopharmaceutical company specialized in oncology, recently announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation (ODD) for ABTL0812, its PI3K/Akt/mTOR pathway inhibitor, for the treatment of the pediatric cancer neuroblastoma and that it has received positive Scientific Advice from the European Medicines Agency (EMA) for its development in the same indication.

  6. bioTheranostics Announces Collaboration With DeNovo Sciences To Evaluate Its Proprietary Cancer Biomarkers For Use In Liquid Biopsies

    bioTheranostics, Inc., a leader in molecular diagnostics for cancer, recently announced a collaboration agreement with DeNovo Sciences, Inc., an innovator in the emerging liquid biopsy field, to investigate the technical feasibility of utilizing bioTheranostics’ proprietary biomarkers in the development of blood-based diagnostics.

  7. Merck Millipore Adds Protein Pegylation To Portfolio Of Services For Biopharmaceutical Industry Through Collaboration With celares GmbH

    Merck Millipore, the Life Science business of Merck, announced a collaboration with celares GmbH to provide pegylation services to customers developing protein-based therapeutics and biosimilars.

  8. U.S. FDA Affirms Functional Equivalence Of DuPont Tyvek

    Recently, DuPont Protection Technologies (DuPont) received notification from the Center for Devices and Radiological Health (CDRH) at the U.S. Food and Drug Administration (FDA) affirming the functional equivalence of transition Tyvek to current Tyvek for sterile medical packaging.

  9. Jarden Life Sciences Examines Solutions To Temperature-Sensitive Pharmaceutical Sampling

    Jarden Life Sciences recently published a white paper discussing available strategies to help to reduce risk and variability in temperature-sensitive pharmaceutical sampling.

  10. ISPE Opens Its Doors To The ISPE Training Institute

    Recently, the International Society for Pharmaceutical Engineering (ISPE) is announcing the opening of the ISPE Training Institute located in its Tampa, Florida office.